Morphic Holding Inc (31Y.SG)
| Previous close | 19.51 |
| Open | 18.66 |
| Bid | 18.39 x N/A |
| Ask | 19.83 x N/A |
| Day's range | 18.66 - 18.66 |
| 52-week range | 17.90 - 57.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMorphic to Participate in RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET. A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will
Simply Wall St.Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda
